Sarepta Therapeutics (NASDAQ:SRPT) Lowered to "Inline" Rating by Evercore ISI

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) was downgraded by investment analysts at Evercore ISI from an "outperform" rating to an "inline" rating in a report issued on Thursday, MarketBeat.com reports. They currently have a $50.00 price objective on the biotechnology company's stock. Evercore ISI's target price would indicate a potential upside of 37.32% from the company's previous close.

Several other equities research analysts have also recently commented on the stock. Scotiabank dropped their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. HC Wainwright dropped their target price on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada dropped their target price on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a research report on Wednesday, May 7th. Cantor Fitzgerald dropped their target price on shares of Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Finally, Oppenheimer dropped their target price on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $131.22.

Sarepta Therapeutics Trading Up 0.1%

SRPT traded up $0.04 during trading on Thursday, hitting $36.41. 3,669,694 shares of the stock traded hands, compared to its average volume of 1,656,680. The firm has a 50-day moving average of $65.42 and a 200 day moving average of $99.77. Sarepta Therapeutics has a 12-month low of $34.95 and a 12-month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a market capitalization of $3.58 billion, a P/E ratio of 29.13 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The company had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. During the same period in the prior year, the business posted $0.73 earnings per share. The company's revenue for the quarter was up 80.2% on a year-over-year basis. Equities research analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.70% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. grew its stake in shares of Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after acquiring an additional 12,000 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of Sarepta Therapeutics in the fourth quarter worth approximately $3,829,000. Nordea Investment Management AB grew its stake in shares of Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock worth $8,228,000 after acquiring an additional 10,815 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of Sarepta Therapeutics by 16,717.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock worth $10,602,000 after acquiring an additional 84,926 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of Sarepta Therapeutics by 24.4% in the fourth quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company's stock worth $10,315,000 after acquiring an additional 16,658 shares during the period. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.